

M

MEDCO FORUM[®]

PRESENTING INNOVATIVE PRODUCTS & SERVICES TO HEALTHCARE PROFESSIONALS

VOLUME 11 NUMBER 62

DECEMBER 2004

REPRINT

SYSMEX XE™—SERIES AUTOMATED HEMATOLOGY ANALYZER UTILIZES FLORESCENT FLOW CYTOMETRY TO PROVIDE RELIABLE DIFF RESULTS

The XE-Series™, produced by **Sysmex America, Inc.**, reliably provides accurate WBC, RBC, PLT, and Differential results using advanced patented Fluorescent Flow Cytometry technology and state-of-the-art cell counting methods. Sysmex received FDA clearance of the hematopoietic progenitor cell (HPC) extended differential parameter on the **XE-2100™** Automated Hematology Analyzer in 2002 and clearance for the immature granulocyte (IG) parameter on the device the following year.

The XE-2100 detects HPCs in the unique IMI channel. The extended differential parameter enumerates HPCs in their distinct cluster on the IMI scattergram. Clinicians may use this HPC enumeration to predict the optimal time to harvest stem cells in patients undergoing mobilization for autologous or allogeneic stem cell transplantation. The XE-2100 system rapidly enumerates HPCs circulating in peripheral blood, which makes testing on the day of a planned apheresis procedure possible. Same-day testing provides results rapidly, enabling the physician to decide whether to begin the procedure, thus optimizing patient outcomes.

The HPC parameter is also capable of estimating stem cell content in umbilical cord blood products with high CD34 cell count and colony forming unit (CFU) activity. Identifying units with high content of viable HPCs that would otherwise not meet the minimum criteria for processing is beneficial to umbilical cord blood banks.

The IG parameter provides a quantitative IG count for metamyelocytes, myelocytes, and promyelocytes

via the XE-2100's Differential Channel, which uses the Sysmex Fluorescent Flow Cytometry technology. This patented technology reduces labor-intensive WBC procedures, reduces false-positive results without increasing false negatives, and improves turnaround time of results critical to patient care. Clinical implications of rapid, automated IG enumeration include screening patients for infectious diseases and myeloproliferative disorders, thus resulting in early diagnosis and intervention.

Based in Mundelein, IL, Sysmex America, Inc. is the U.S. headquarters of Sysmex Corporation



(Kobe, Japan), a leading international manufacturer of medical diagnostic systems focused on hematology, hemostasis, immunochemistry, particle counting, urinalysis, and laboratory information systems. To meet the needs of different global areas, Sysmex

has its own corporate network of marketing, production, and research and development in 14 countries, including Sysmex America, Inc. Sysmex offers customized in vitro diagnostics and IT solutions that enhance clinical information and increase productivity by integrating technological innovation, automation platforms, and information solutions for all of its customers around the world.

For more information concerning the XE-Series of products, call Sysmex America at 1-800-379-7639, or visit Sysmex America, Inc.'s Web site at www.sysmex.com/usa.

Medco Forum® is a registered trademark of Medco Communications LLC Copyright © 2004 Medco Communications LLC. On editorial matters or to request additional copies, telephone (303) 674-9607. Any reproduction, in whole or in part, without express written permission of publisher is prohibited. The information and statements directed to the products discussed herein are based solely on information and statements received from manufacturers and/or distributors thereof. The publishers do not warrant and assume no liability for the accuracy of the information contained herein. The manufacturers and/or distributors should be contacted for any and all information that the reader may desire. Send inquiries or comments regarding this publication to: Medco Communications LLC, 87 Oak Way, Evergreen, CO 80439.